Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
This new facility strengthens Latin America as a collaborative hub
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
These findings follow positive Phase 3 results presented earlier this year
The new plant will manufacture high-quality Type I borosilicate glass tubing
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
